Intra-Cellular Therapies (“ITCI”) Stock Soars While Key Clinical Data Not Presented to Shareholders Looks Highly Disappointing
(July 15th, 2015) Biotech stocks have been on fire. And for good reason as numerous life-saving discoveries have come out of small, previously-unknown firms, making their owners rich many times over. But beneath the surface, a number of troubling drug development companies have caught the attention of investors with clinical data that’s dubious at best. With seemingly endless amounts of optimism, these biotech stocks have ridden the wave of investor enthusiam even when the data doesn’t look as promising as the market caps seem to indicate.
All You Ever Wanted to Know About Retrophin But Were Afraid to Ask
(June 2nd, 2014) Humans, like atoms, abhor unsteady states of existence. Just like electron transport gravitates towards a steady-state, people gravitate towards peaceful lands and away from battleground areas. Read more
Know What to Buy When Putin Comes Knocking
So Putin rolls a bunch of tanks up to the Ukrainian border and the market slides a percent or so. In any other market that would be considered a yawn. But here in the good ‘ol US of A, where the average active investor can barely remember the dog days of ’08, few traders seem to have the skill set necessary to maneuver in a down market. Having done this for 20+ years, I thought it would be helpful to share my trading tips for when war comes knocking.
Is There Any Meaningful ACTH in Acthar Gel?
The accusations leveled against Questcor (Nasdaq: QCOR) by Citron Research this morning are frightening. Truly frightening. And I don’t mean for those shareholders unlucky enough to call themselves owners of this HP Acthar franchise. No, I’m talking about the kids. Read more
Cutting Through all the Noise at Retrophin
I have to admit to a dilemma. Since purchasing a little over 1% fully-diluted of Retrophin, Inc. (Nasdaq: RTRX) last summer in the $4.50/sh PIPE and subsequently tweeting about the company, I’ve built up quite a number of readers who look to me for advice and analysis regarding Retrophin. Read more